Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis

被引:17
作者
Zhang, Zhengmao [1 ]
Dou, Xiaomeng [1 ]
Yang, Hongfang [2 ]
Jia, Ling [1 ]
Qin, Kaiyun [3 ]
Gao, Xingshuang [3 ]
Yang, Botao [1 ]
Zhang, Wenzhe [4 ]
Qin, Congying [1 ]
Zhang, Fenghua [5 ]
Shan, Baoen [6 ]
机构
[1] Hebei Med Univ, Hosp 4, Dept Gynaecol, Shijiazhuang 050011, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Lab Med, Shijiazhuang 050011, Peoples R China
[3] Hebei Gen Hosp, Dept Gynaecol, Shijiazhuang 050051, Peoples R China
[4] Hebei Med Univ, Hosp 4, Dept Gynaecol & VIP, Shijiazhuang 050011, Peoples R China
[5] Hebei Gen Hosp, Dept Gen Surg, Shijiazhuang 050051, Peoples R China
[6] Hebei Med Univ, Hosp 4, Dept Res Ctr, 12 Jiankang Rd, Shijiazhuang 050011, Peoples R China
关键词
Ovarian cancer; p53; Livin; Chemo-Resistance; Prognosis; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE-1; PLATINUM RESISTANCE; PROTEIN EXPRESSION; APOPTOSIS PROTEIN; EXCISION-REPAIR; SURVIVAL; CHEMOTHERAPY; INHIBITOR; MUTATIONS;
D O I
10.1016/j.prp.2019.152794
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objective: To evaluate the correlation between expression of p53, Livin, Excision repair cross-complementation group 1 (ERCC1), BRCA1 and Poly (ADP-ribose) polymerase 1 (PARP 1) in epithelial ovarian cancer (EOC) tissues with platinum-based chemotherapy and prognosis in patients who received either comprehensive surgical staging or cytoreductive surgery. Methods: The protein expressions level of five potential regulators involved in chemo-resistance, including p53, Livin, ERCC1, BRCA1 and PARP1 in EOC tissues from 66 patients were evaluated using immunohistochemistry method. We also measured preoperative CA125 level measured by an electrochemiluminescence immunoassay (ECLIA) in all patients. Cox proportional hazard regression model was established to identify whether these proteins are associated with overall survival. Results: Chemo-resistance and poor overall survival were shown to be significantly related with positive expressions of p53, Livin, ERCC1, BRCA1 and PARP1. The evaluation of risk factors on the chemo-resistance showed that ERCC1 and BRCA1 are strong risk factors (OR: 21.12 and 21.61, all P < 0.01), while the positive expression of ERCC1, BRCA1 and PARP1 was significantly highly associated with the overall survival (HR: 3.9, 3.7 and 2.6, all P < 0.05, respectively). CA125 levels were significantly higher in patients with positive expression of P53, BRCA1, ERCC1 or Livin compared with those with negative expression (471:146, 667:260, 494:261 and 4589:89 U/ml, respectively, all P < 0.05). Conclusions: The elevated expression levels of ERCC1 and BRCA1 were identified as significant risk factors for chemo-resistance in EOC. Reduced expression levels of ERCC1, BRCA1 and PARP1 were significantly associated with better overall survival. The CA125 levels were significantly higher in patients with EOC specimens that were positive of p53, BRCA1, ERCC1 and Livin.
引用
收藏
页数:8
相关论文
共 51 条
[41]   Hereditary ovarian cancer [J].
Russo, Antonio ;
Calo, Valentina ;
Bruno, Loredana ;
Rizzo, Sergio ;
Bazan, Viviana ;
Di Fede, Gaetana .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 69 (01) :28-44
[42]   No Association between BRCA1 Immunohistochemical Expression and Tumor Grade, Stage or Overall Survival in Platinum-Treated Epithelial Ovarian Cancer Patients [J].
Shawky, Abd El-Aty ;
Abd El-Hafez, Amal ;
El-Tantawy, Dina ;
Hamdy, Rasha .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (10) :4275-4279
[43]   The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer [J].
Steffensen, Karina Dahl ;
Waldstrom, Marianne ;
Jakobsen, Anders .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (05) :820-825
[44]   Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas [J].
Swisher, Elizabeth M. ;
Gonzalez, Rachel M. ;
Taniguchi, Toshiyasu ;
Garcia, Rochelle L. ;
Walsh, Tom ;
Goff, Barbara A. ;
Welcsh, Piri .
MOLECULAR CANCER, 2009, 8 :48
[45]   Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801) [J].
Tang, Amy ;
Kondalsamy-Chennakesavan, Srinivas ;
Ngan, Hextan ;
Zusterzeel, Petra ;
Quinn, Michael ;
Carter, Jonathan ;
Leung, Yee ;
Obermair, Andreas .
GYNECOLOGIC ONCOLOGY, 2012, 126 (01) :36-40
[46]   PARP inhibitors: A new era of targeted therapy [J].
Tangutoori, Shifalika ;
Baldwin, Paige ;
Sridhar, Srinivas .
MATURITAS, 2015, 81 (01) :5-9
[47]   Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry [J].
Veskimae, K. ;
Staff, S. ;
Gronholm, A. ;
Pesu, M. ;
Laaksonen, M. ;
Nykter, M. ;
Isola, J. ;
Maenpaa, J. .
TUMOR BIOLOGY, 2016, 37 (09) :11991-11999
[48]   Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair [J].
Veuger, SJ ;
Curtin, NJ ;
Smith, GCM ;
Durkacz, BW .
ONCOGENE, 2004, 23 (44) :7322-7329
[49]   Sequential assembly of the nucleotide excision repair factors in vivo [J].
Volker, M ;
Moné, MJ ;
Karmakar, P ;
van Hoffen, A ;
Schul, W ;
Vermeulen, W ;
Hoeijmakers, JHJ ;
van Driel, R ;
van Zeeland, AA ;
Mullenders, LHF .
MOLECULAR CELL, 2001, 8 (01) :213-224
[50]   Challenge and promise: roles for Livin in progression and therapy of cancer [J].
Wang, Ling ;
Zhang, Qi ;
Liu, Bin ;
Han, Mei ;
Shan, Baoen .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (12) :3661-3669